As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community. Innovation represents one of the strongest pillars of the company with more than 50 in-house scientists and a unique network of talented and renowned medical doctors contributing to Regen Lab’s Research & Development.

Over nearly 15 years, this innovation has been secured by building substantial patent & trademarks portfolios. Intellectual Property Rights (IPRs) therefore represent core assets of the company protecting its unique products and forging Regen Lab’s renowned brand names.

The patent portfolio can be divided into two core technologies:

1-PRP/BMC gel devices, methods and uses thereof, alone or in combination with cell extracts and associated key technologies like Autologous Thrombin Serum (ATS) and PRP Cell Culture.

Associated trademarks are REGENLAB®, REGENKIT®, REGENACR®, PRP®, A-PRP®, REGENCELL®, REGENPLASMA®, REGEN PRP®, REGEN®, REGEN EXTRACELL®, THT®, cellularmask®, CUTECELL®, REGENVET®, A-CPKIT® which are registered trademarks of REGEN LAB SA in Europe, United States and other countries.

2-Hyaluronic acid alone, cross-linked or not, or in combination with PRP/BMC leading to the unique “all in one” Cellular Matrix products combining in a synergetic manner the advantageous properties of PRP and HA, but also preparation in two separate devices.

Associated trademarks are REGENLAB®, REGENKIT®, CELLULAR MATRIX® fig., SKINVISC®, ARTHROVISC®, REGENMATRIX®, REGEN®, PRP® and A-PRP® which are registered trademarks of REGEN LAB in Europe, United States and other countries.

V2023.1 January 26, 2023



[not limited to]

[not limited to]

A-PRP & BMC, glue and membranes
Combination with Cell Extracts, Cell Culture

RegenACR®,  RegenKit® Surgery, RegenKit® BCT, A-CP Kit®, Regen Fibrin Polymer, RegenKit® Extracell – Regen Extracell®, Regencell®, THT®,  Cutecell®, A-PRP®, REGENPRP®, REGEN®, PRP®, Regenvet®

Granted US11241458, US11110128, US11096966, US10881691, US10092598, US10080770, US10064894, US8529957, US9833478, US10052349, US11241458, US11389482, EP3395383B, EP3111974B1, CH696752, HK1231793 FTO restricted with gel technology.

Pending U.S. Serial 17/837,825, EP22200374.1, WO2008/023026, WO2011/110948, WO2016/083549, WO2019/155391

ATS alone or combination with A-PRP for biological glues and membranes

RegenKit® ATS Granted US10226516, EP3403659B, AU2013203115B, JP6359495, JP6588499, CA2915649, IL252122, KR10-2136314, IN330984, HK1179507

FTO restricted with gel technology.


Pending WO2011/110948, CN105998067, CN202211204780.2, RU2018133055/20

Combination therapy: A-PRP & Hyaluronic Acid

Cellular Matrix® fig. kits (linear HA)

RegenMatrix® (X-linked HA)


Granted US10272139, US8945537, US9517255, US10052349, EP2544697B1, EP3184114B, EP2771241B, CA2789533C, JP6076091, JP6321119, JP6892485, AU2011225828B, IL221133, RU2614722, RU2667964, KR20130067247, IN330984, HK1179507

US11077241, EP3223875B, AU20150352458B, EA035982B, MA40376B, IL252536, MX382517, UA123822, KR102362722B1, BR112017010837, BH1857-20220915

None for sale.
FTO restricted with gel technology.
FTO restricted with HA in centrifugation tube.

Pending WO2011/110948, WO2013/061309, WO2019/155391
– US2019201504, US2018327120, CN112220802, EP3854406, HK42021040392.9, HK40050052
– CA2968731, CL20170001357, CN20158073651, CR20170000288, JP2017536892, JP2018164757, P20180135503, KR20170088366, PE20170931, PH20171500946, SG20171104218P, TN20170000220, US2018110917
– AU2019218711, CA3089896, GCC2019/38117, EP3743079, JP2021515088, US2022193116, TW108128394, CN112118849, HK62020021959.5, KR20200130685

Cellular Wound

Granted IL284309, AU2021201102B2
Pending EP3903844, KR10-2022-7004415, HK42021044735.5, US2021346587

Hyaluronic Acid only Arthrovisc®, Skinvisc® Pending WO2019/155391, WO2013/061309

From third-parties only.


Regenplasma®/A-CP Pending WO2021/198312, CA3170584, AU2021249444, EP4114526, US serial no. 17/916,507

None for sale.


None for sale.




Contact Regenlab

Now is the time to change your patient’s life. Browse ressources and
get connected to treatment that is right for them.

For more information on our products, please contact us by clicking on the button below:


Our Regional offices are
located in

  • New York (USA)
  • Montréal (Canada)
  • Venice (Italy)
  • Munich (Germany)
  • Paris (France)
  • Dubai (U.A.E.)
  • Beijing (China)
  • and Istanbul (Turkey)